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Summary
QUESTION UNDER STUDY: The aim of this study was
to assess the feasibility, acceptability and effectiveness of
a pilot COPD integrated care programme implemented in
Valais, Switzerland.
METHODS: The programme was adapted from the self-
management programme Living Well with COPD, and in-
cluded the following elements: self-management patient-
education group sessions, telephone and medical follow-
ups, multidisciplinary teams, training of healthcare pro-
fessionals, and evidence-based COPD care. A process
and outcome evaluation of the pilot phase of the pro-
gramme was conducted by means of qualitative and quan-
titative methods. Reach (coverage, participation rates),
dosage (interventions carried out), fidelity (delivered as in-
tended) and stakeholders’ acceptance of the programme
were evaluated through data monitoring and conduct of
focus groups with patients and healthcare professionals.
Effectiveness was assessed with pre-post analyses (be-
fore and after the intervention). The primary outcome mea-
sures were; (1) generic and disease-specific quality of life
(36-Item Short Form Health Survey, Chronic Respiratory
Questionnaire); and (2) hospitalisations (all-cause and for
acute exacerbations) in the past 12 months. Secondary
outcomes included self-efficacy, number of exacerbations
and exercise capacity. Finally, controlled pre-post compar-
isons were also made with patients from the Swiss COPD
Cohort for three common outcome measures (dyspnoea
[mMRC score], number of exacerbations and smoking sta-
tus).
RESULTS: During the first 2 years of the programme,
eight series of group-based education sessions were de-
livered to 57 patients with COPD in three different loca-
tions of the canton of Valais. Coverage objectives were
achieved and attendance rate at the education sessions
was high (83.6%). Patients’ and healthcare professionals’
reported a high degree of satisfaction, except for multidis-
ciplinarity and transfer of information. Exploration of the
effectiveness of this pilot programme suggested positive
pre-post results at 12 months, with improvements in terms
of health-related quality of life, self-efficacy, exercise ca-
pacity, immunisation coverage and Patient Assessment of
Chronic Illness Care score. No other outcome, including
the number of hospital admissions, differed significantly
after 12 months. We observed no differences from the
control group.
CONCLUSIONS: The evaluation demonstrated the feasi-
bility and acceptability of the programme and confirmed
the relevance of mixed method process evaluation to ad-
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just and improve programme implementation. The intro-
duction of multidisciplinary teams in a context charac-
terised by fragmentation of care was identified as the main
challenge in the programme implementation and could
not be achieved as expected. Despite this area for im-
provement, patients’ feedback and early effectiveness re-
sults confirmed the benefits of COPD integrated care pro-
grammes emphasising self-management education.
Trial registration number: ClinicalTrials.gov, identifier
NCT02001922.
Key words: COPD, integrated care, education and self-
management, mixed methods, programme evaluation,
community
Introduction
Chronic obstructive pulmonary disease (COPD), which
presents as a progressive airflow obstruction associated
with systemic comorbidities such as sarcopenia, and is-
chaemic heart and metabolic diseases, is now the third
cause of mortality worldwide [1]. COPD is characterised
by acute exacerbations, which are responsible for frequent
emergency visits and hospitalisations, as well as deaths.
These acute exacerbations also durably reduce quality of
life and put a high burden on the healthcare system, not on-
ly in terms of health but also in terms of healthcare costs
[2].
Current care for COPD is usually based on inhaled phar-
macotherapy for symptom relief and prevention of exacer-
bations, but often neglects the systemic impact of COPD
and patients’ perspectives on care. In addition, the quality
of COPD care is suboptimal and does not always reflect
current guidelines. For example, Swiss and Canadian stud-
ies have shown that pulmonary rehabilitation is largely un-
derprescribed and inhaled corticosteroids are prescribed to
patients despite disease severity not requiring them [3–5].
A study conducted in the United States reported that
COPD patients received only 58% of recommended care
[6]. Studies have suggested several explanations, at the
healthcare professional and patient levels, for inappropri-
ate care and poor outcomes. At the healthcare professional
level, primary care physicians may lack familiarity with
clinical evidence, they may lack confidence in diagnosing
and staging COPD, and they may face time constraints
[7]. At the patient level, patients may lack information and
skills to perform self-care, as well as confidence and mo-
tivation, especially when it comes to engaging in regular
physical activity and perform recommended self-care ac-
tivities. In addition, depression and anxiety, which are as-
sociated with low self-efficacy, have been shown to predict
low levels of physical activity in COPD [8].
In this context, integrated care programmes, based on the
Chronic Care Model [9, 10], can contribute to overcoming
patient and healthcare professional barriers to appropriate
care, and, hopefully, to closing the observed quality care
gap. Integrated care is a polymorphous concept that was
developed within the context of an ageing population and
the rise in long-term conditions, and which promotes pa-
tient-centeredness and care coordination [11]. Integrated
care programmes, which focus on long term behavioural
change and self-management support, foster formal con-
tacts between healthcare providers and multidisciplinary
care, promote evidence-based care such as early detection
and management of acute exacerbations, and encourage
physical activity, healthy diet, smoking cessation and ad-
herence to medication. These programmes have been
shown to improve health-related quality of life, exercise
capacity and hospital admissions in COPD patients
[12–14]. In addition, and despite their heterogeneity, inte-
grated care programmes for COPD were found to be cost-
effective [15].
Whereas European countries such as the Netherlands, the
UK, Germany and Spain started implementing integrated
programmes almost two decades ago, developments in
Switzerland are more recent and programmes often lack
resources for appropriate implementation and evaluation
[16]. However, an ongoing study, aimed at identifying and
describing integrated care initiatives in Switzerland, iden-
tified 162 integrated care initiatives, two of which specif-
ically targeted COPD (Schusselé-Fillietaz, personnal com-
munication, October 2016). Based on the Chronic Care
Model and Bourbeau’s “Living Well with COPD” pro-
gramme [17, 18], two integrated care programmes were
implemented in two different Swiss regions, the cantons of
Zurich [19] and Valais.
The canton of Valais is a rural and alpine region char-
acterised by a homogeneous but geographically dispersed
population, a low population density, and lower density of
general practitioners and specialised healthcare providers
compared with the rest of Switzerland. Solo practices re-
main the norm, and medical homes and care networks did
not exist at the time of the programme implementation. Im-
plementing a multidisciplinary integrated care programme
in such a setting was an innovative challenge. Hence, the
aims of the present evaluation were: first, to assess the fea-
sibility and acceptability of the implementation of a pi-
lot COPD evidence-based integrated care programme in an
alpine and rural Swiss canton, and second, to explore its
effectiveness.
Methods
Study design
For this process and outcome evaluation, we used a mixed-
methods approach. The qualitative part consisted of focus
groups of COPD patients and healthcare professionals to
assess the feasibility and acceptability of the programme.
The quantitative part consisted in the data collection of
both clinical and self-reported survey measures to assess
the effectiveness of the programme. We conducted pre-
post analyses on these latter measures, with a matched con-
trol group for three comparisons.
The study protocol was reviewed and approved by the
Cantonal Ethics Committee of the Canton of Valais (De-
cember 2012; No. CCVEM 046/12).
Participants and recruitment (health professionals and
patients with COPD)
Healthcare professionals residing in the French-speaking
part of the canton of Valais, Switzerland, were recruited
through individual visits to their practice or group infor-
mation sessions, during which information on programme
participation, programme implementation, and guidelines
for treatment and management of COPD were provided.
General practitioners and pulmonologists were in charge
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of recruiting patients, meeting them regularly and encour-
aging them to follow the medical recommendations. The
pulmonologists were also invited to collaborate in the de-
velopment of the patient action plan and could intervene
during education sessions, along with physiotherapists and
pharmacists. Pharmacists were also prompted to distribute
flyers at their pharmacies, strengthen the smoking cessa-
tion message and offer polypharmacy consultations. Final-
ly, all healthcare professionals were encouraged to take
part in the multidisciplinary seminars and training sessions
organised within the context of the programme.
Patients recruited by healthcare professionals were con-
tacted by the programme coordinator, who gave them in-
formation about the programme, verified eligibility criteria
and asked for written consent. Patients with a diagnosis
of COPD (GOLD stage I–IV or B-C-D), aged 35 years
and over, not institutionalised and residing in the French-
speaking part of the canton of Valais in Switzerland were
eligible to participate in the pilot programme. Patients
were excluded if they had cognitive problems, their level
of French was insufficient, or their life expectancy was less
than 12 months. Patients in the control group were sampled
from the Swiss COPD Cohort [3, 4] and matched with the
programme participants on age, gender and COPD Assess-
ment Test (CAT) scores.
Intervention
The pilot programme, called “Soins intégrés BPCO Valais
– Mieux vivre avec une BPCO”, was based on the Chronic
Care Model (CCM) and the Canadian programme “Living
Well with COPD: A Plan of Action for Life” [18, 20, 21].
Before the implementation of the programme, we conduct-
ed focus groups with healthcare professionals to discuss
the appropriateness and feasibility of the key components
of the programme [9, 10, 22].The programme, as imple-
mented in 2013 and 2014, included the following elements
(fig. 1):
1. Patient education and self-management, the key com-
ponent of the programme consisted of six weekly
group-based self-management education sessions
(90–120 minutes per session), led by a respiratory
physiotherapist and/or a nurse specialised in self-man-
agement support, accompanied by a pulmonologist
and a pharmacist during two specific sessions, as well
as two individual sessions that took place once before
and once after the six group sessions. Topics covered
by the group-based sessions included disease educa-
tion, medication, breathlessness and stress manage-
ment, prevention and management of exacerbations,
and lifestyle behaviours (physical activity, smoking
cessation, healthy diet, good sleep habits, satisfying
sexual life, leisure activities). Educational materials of
the Canadian programme, including the action plan,
were adapted to the local context, in collaboration with
the team led by Professor Bourbeau from McGill Uni-
versity.
2. Scheduled follow-up. Proactive telephone-call follow-
ups (every 4–6 weeks) were continued for up to 12
months after inclusion in the programme; patients
were invited to regularly consult their general practi-
tioner (three to four times per year) and pulmonologist
(twice per year).
3. Multidisciplinarity was encouraged by regular formal
meetings, to enhance the collaboration between health-
care professionals involved in the management of
COPD and, ultimately, to improve care coordination.
To this end, tasks and responsibilities of each health-
care professional were defined before the implementa-
tion. The programme coordinators (specialised physio-
therapist and nurse), assisted by participating pulmo-
nologists, were in charge of the recruitment, organi-
sation and conduct of the self-management education
sessions, the follow-up and hotline telephone calls,
the transfer of information between professionals and
the data collection process. General practitioners and
Figure 1: Life cycle of the programme.
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pulmonologists participated in patient recruitment and
collected medical data; they also continued the regular
evidence-based care follow-up of their patients and en-
couraged them to change behaviours. Pulmonologists
were also in charge of discussing and writing action
plans. Physiotherapists and pharmacists were invited
to reinforce COPD care messages. Finally, profession-
als of all care groups could co-facilitate group sessions
and offer specific additional support to patients (e.g.,
pulmonary rehabilitation, medication therapy manage-
ment).
4. Information to and training of healthcare profession-
als. We held several seminars on COPD management
and training sessions on the content of group-based
self-management sessions, and notified the patient’s
primary healthcare provider of their patient’s participa-
tion in the programme and sent the action plan.
5. Evidence-based COPD care was encouraged through
the distribution of GOLD pocket guidelines to health-
care providers [23].
Data collection
Qualitative data were collected via focus groups conducted
with patients and healthcare professionals during and at
the end of the programme, and quantitative data were col-
lected at baseline (during the first visit of the programme)
and after 12 months of participation. Baseline data includ-
ed various self-reported health-related and personal vari-
ables and medical data reported by the patient’s physician.
At 12 months, self-reported data and data on physical ac-
tivity were collected during an individual session.
For the control group, we extracted data from the Swiss
COPD Cohort database.
Measurements
Process evaluation: feasibility and acceptability mea-
sures
Based on the literature [24–27], we decided to measure
four process indicators: reach, dosage, fidelity to assess the
programme’s feasibility (defined as the extent to which an
intervention can be carried out in a particular setting) and
acceptability.
– Reach refers to the degree to which the population that
is eligible to benefit from an intervention actually re-
ceives it. In our study, we focused on patient and health-
care professional participation rates.
– Dosage relates to the “amount” of the programme’s
content that was actually delivered to participants. We
operationalised it by counting the number of learning
materials printed and distributed, the number and loca-
tion of group-based education sessions delivered, the
mean number of telephone follow-up contacts, the num-
ber of seminars/symposiums organised for healthcare
professionals, etc.
– Fidelity refers to the degree to which an intervention
was implemented according to the original protocol. It
was evaluated by comparing the protocol written in De-
cember 2011 to what had indeed been done in the field
(dosage), as described in the 2012 and 2013 annual re-
ports
– Acceptability refers to the stakeholders’ perceptions
that an intervention is agreeable, satisfactory. It was as-
sessed using data from the focus groups organised to
discuss participating patients and healthcare profession-
als’ opinions on, and experiences with, the programme.
We organised two focus groups with patients (n = 11)
and three focus groups with healthcare professionals (n
= 22: six general practitioners, four pulmonologists,
eight pharmacists, three physiotherapists and one tobac-
cologist) in 2013 and 2014. We also used data from a
patient satisfaction questionnaire sent at the end of the
programme (12 months) to assess its acceptability.
Outcome evaluation: effectiveness measures
In contrast to “efficacy” trials, which are conducted in set-
tings that maximise the management of and the control
over the research process, “effectiveness” evaluations aim
“to measure the impact of an intervention when it is tested
within a population that is representative of the intended
target audience.” [28]. An effective programme is thus de-
fined as “a programme [that] does more good than harm
when delivered under real-world conditions” [29]. We as-
sessed effectiveness by conducting pre-post analyses (be-
fore and after the intervention) on several primary and sec-
ondary outcomes, and comparing three of these outcomes
with those in a matched control group.
Our two primary outcomes were health-related quality of
life and hospital admissions in the past 12 months, two key
indicators in the field of integrated care programme gen-
erally [30] and COPD management more specifically [13,
14].
Health-related quality of life (HRQoL) was measured us-
ing two self-administered questionnaires: (1) the Chronic
Respiratory Questionnaire (CRQ), a disease-specific in-
strument comprising 20 questions on a seven point Likert-
type scale, producing four domain scores for dyspnoea,
mastery, fatigue and emotion (scores ranged from 0 to
7, a higher score indicating better quality of life) [31,
32]; (2) the 36-Item Short Form Health Survey (SF-36), a
generic instrument measuring eight dimensions of health:
physical functioning, role limitations due to physical prob-
lems, bodily pain, general health, vitality, social function-
ing, role limitations due to emotional problems, mental
health (scores ranged from 0 to 100, with 100 indicating
better quality of life) [33–35].
We used two indicators for hospital admissions: the pro-
portion of patients with one or more hospitalisations (all-
causes) in the past 12 months and the proportion of patients
with one or more hospitalisations for acute exacerbations
in the past 12 months.
We also measured the following secondary outcomes:
– self-efficacy, measured with the Self-Efficacy for Man-
aging Chronic Disease 6-Item Scale [36] which was
adapted to the management of COPD (scores ranged
from 1 = not at all confident to 10 = totally confident);
– a global measure of the impact of COPD on daily life,
the COPD Assessment Test (CAT) score (total score
ranges from 0 to 40; <10 indicates low impact, 10–20
medium impact, 21–30 high impact, >30 very high im-
pact on life) [37];
– dyspnoea, measured with the modified Medical Re-
search Council scale” (mMRC) (grade 0 “I only get
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breathless with strenuous exercise” to grade 4 “I am too
breathless to leave the house or I am breathless when
dressing”) [38, 39];
– number of COPD exacerbations, as the patient-reported
average number of exacerbations during the past 12
months, and the proportion of patients reporting ≥1 ex-
acerbations during that same period;
– physical capacity, using the Six-Minute Walk Test [40]
and the Sit-to-Stand Test [41, 42];
– healthcare services utilisation, with the average number
of visits to physicians (family physician and pulmo-
nologist) during the past 12 months, and emergency de-
partment visits / unscheduled physician visits during the
same period;
– smoking status, seasonal influenza vaccination and
pneumococcal vaccination status;
– respiratory drugs prescribed, and
– care congruence with the Chronic Care Model (CCM),
using the Patient Assessment of Chronic Illness Care”
questionnaire (PACIC) (20 questions on a five point
Likert-type scale, 1 = never to 5 = always; mean scores
ranged from 1 to 5, with 5 representing the greatest con-
gruence with the CCM) [43, 44].
We also collected sociodemographic data (age, gender, re-
lationship status, living situation, education, employment
status, type of residence, insurance status, nationality) and
health status data (body mass index, lung function).
Data analysis
Qualitative data analysis
The focus groups, conducted with a pre-established inter-
view guide, were recorded and fully transcribed; content
analysis [45, 46] was used to extract the arguments associ-
ated with each topic under discussion.
Quantitative data analysis
Descriptive analyses were carried out first, with data re-
ported as means or percentages for continuous or categor-
ical variables, respectively. We then used bivariate analy-
ses to compare before and after measures of all primary
and secondary outcomes; paired t-tests and McNemar tests
were considered for continuous and categorical variables,
respectively. Only data from patients who participated in
the evaluation at 12 months were included in the analyses.
In order to compare the results between the patients partic-
ipating in the programme and the patients from the Swiss
COPD Cohort, we first selected a control group (two con-
trols per case), performing a propensity score matching for
age, gender and CAT score [47]. We then analysed over-
time differences within groups for three commonly avail-
able outcome variables: dyspnoea (mMRC score), the pro-
portion of patients reporting ≥1 exacerbations during the
last 6/12 months, and smoking status. The confidence in-
tervals (CIs) for mean paired differences were computed
with the Student distribution for continuous variables and
a method developed by Newcombe [48] for dichotomous
variables. We then computed the between group differ-
ences of within group differences. For continuous vari-
ables, we used a Student confidence interval for the mean
difference of two independent samples and for the dichoto-
mous variables we used a method developed by New-
combe [49] to compare differences of paired differences of
proportions. Statistical significance was set at p <0.05, and
all analyses were performed using Stata 14.
Results
Process evaluation: feasibility and acceptability
Reach
For this pilot phase of the programme, we aimed to include
between 30 and 50 patients over 2 years (2013–2014), with
a follow-up of 12 months. Between 2013 and 2014, 83 pa-
tients were identified during the recruitment process. Of
these, 57 patients were eligible and consented to participate
in the study; 3 did not meet the inclusion criteria and 23
declined to participate at a first telephone contact or after
a first meeting with a programme coordinator (specialised
physiotherapist or nurse). The target of 30 to 50 partici-
pants for the pilot phase of the programme was therefore
achieved. The average participation rate in the education
sessions was 83.6%; patients participated in five sessions
out of six on average. Three participants were not pre-
sent at the individual session that followed the six group
sessions, and 46 out of 57 agreed to be assessed at the
12-month follow-up. The 11 non-adherent patients at the
12-month evaluation did not differ significantly from the
participating patients on key demographics, but were less
likely to live alone and presented lower forced expiratory
volume in 1 second (FEV1) and Tiffeneau index.
Baseline characteristics of the participants are presented in
table 1. On average, patients were 66 years old and 56%
were male. Most patients lived with a partner and half were
retired. Two thirds of patients had at least one exacerbation
in the previous year and most had moderate COPD. Demo-
graphics of the participants were similar to the population
of Swiss patients living with COPD and were typical of the
population targeted by comparable interventions [50].
Healthcare professionals participated in patient enrolment
to various degrees: pulmonologists, general practitioners
(GPs) and, pharmacists enrolled 34, 14, 1 patients, re-
spectively. The GP participation rate was weaker than ex-
pected: during the first year of the programme, of the 11
general practitioners who agreed to meet the programme
coordinator, only three finally recruited patients. Further-
more, the response rate to the GP questionnaire was so low
that we stopped sending it to GPs in 2014. On the other
hand, the six half-day seminars on COPD management
were successful, with a mean of 60 participants each time
coming from a wide range of professional backgrounds.
Dosage
During the first 2 years of the programme, eight series of
group-based education sessions took place in three differ-
ent locations in the canton of Valais (Sion, Martigny, Mon-
they). During each series, all six group-based education
sessions were delivered. The teaching material was print-
ed and handed out to all participants prior to education
sessions (469 workbooks and action plans in total for 57
patients and 10 healthcare professionals). Two thirds of
patients received an action plan for acute COPD exacerba-
tions, whereas all patients were offered an individual ses-
sion at home or at the hospital before and after the group
sessions. Patients received telephone calls from the phys-
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Table 1: Baseline characteristics of participants (n = 57 patients with
COPD).
Sociodemographic and general health characteristics
Age (n = 57) 66.0 ± 8.3
Female (n = 57) (43.9)
Marital status (n = 57)
Single 1(1.8)
Married or living with partner 37 (64.9)
Separated, divorced, widowed 19 (33.3)
Education (n = 56)
Primary 18 (32.1)
Secondary 25 (44.7)
Tertiary 13 (23.2)
Employment status (n = 56)
Employed 8 (14.2)
Reduced working time because of
health problem
14 (25.0)
Unemployed, house wife 6 (10.8)
Retired 28 (50.0)
Living alone (n = 57) 15 (26.3)
Habitation (n = 56)
Rural 37 (66.1)
Urban 19 (33.9)
Current smoker (n = 51) 22 (43.1)
Body mass index (n = 57)
Overweight (25–29.9 kg/m2) 17 (29.8)
Obese (≥30 kg/m2) 14 (24.6)
COPD
Lung function (n = 45)
FEV1, % predicted 57.5 ± 18.9
FEV1/FVC 49.9 ± 13.4
GOLD stage* (n = 54)
1: mild (FEV1 ≥ 80% predicted) 5 (9.3)
2: moderate (50% ≤ FEV1 < 80%
predicted)
30 (55.5)
3: severe (30% ≤ FEV1 < 50% pre-
dicted)
13 (24.1)
4: very severe (FEV1 < 30% pre-
dicted)
6 (11.1)
GOLD stage, ABCD classification† (n = 54)
A: low risk, less symptoms 2 (3.7)
B: low risk, more symptoms 21 (38.9)
C: high risk, less symptoms 3 (5.6)
D: high risk, more symptoms 28 (51.9)
mMRC score ‡ (n = 57)
0 3 (5.3)
1 13 (22.8)
2 23 (40.3)
3 14 (24.6)
4 4 (7.0)
CAT score (n = 57) 17.3 ± 7.5
≥1 exacerbations in previous year (n = 46) 31 (67.4)
≥1 hospitalizations in previous year (n = 56) 24 (42.9)
Respiratory treatments (n = 50)
Short-acting β2 agonist 22(44)
Short-acting anticholinergic 4(8)
Long-acting β2 agonist 15(30)
Long-acting anticholinergic 38(76)
Combined long-acting β2 agonist
and inhaled corticosteroids
26(52)
Inhaled corticosteroids 3(6)
CAT = COPD Assessment Test; FEV = forced expiratory volume; FEV1
= forced expiratory volume in 1 second; FVC = forced vital capacity;
mMRC=modified Medical Research Council. Data are presented as
mean ± SD or n (%). * From lung function tests. † From lung function
iotherapist / specialised nurse every 4 to 6 weeks according
to their needs, and the hotline was active five days a week
and was used 42 times by the patients during the 2 years of
the pilot phase. Furthermore, an information campaign was
implemented in order to communicate on the programme
and inform on the COPD management guidelines. Flyers
were distributed in pharmacies and medical offices, articles
were published in the local newspaper, and several confer-
ences and workshops were held.
Fidelity
Intervention reports and monitoring data showed good ad-
herence to the programme protocol. However, the pro-
gramme required several adaptations in order to respond to
local constraints. First, we revised the recruiting method to
be more efficient, by extending the range of healthcare pro-
fessionals authorised to recruit patients and replacing indi-
vidual visits to GPs and pulmonologists by group informa-
tion sessions. Second, the multidisciplinarity component
was underdeveloped in the first 2 years of the pilot phase
of the programme, mainly because considerable effort had
been dedicated to the preparation of the material and the
group-based education sessions instead. Although the pro-
tocol aimed to foster collaboration between the different
healthcare professionals involved in the management of
patients with COPD, in practice, information transfer was
not optimal and GPs’ involvement not sufficient. Third, we
had to stop conducting education sessions in one of the re-
gions because it was difficult to access and it registered
low attendance rates in the first year of the programme.
The group sessions took place in three different towns in
Valais, instead of four as originally planned.
Acceptability
Patient and healthcare professionals perceptions collected
via focus groups at the end of the intervention are sum-
marised in table 2. Overall, patients and professionals were
satisfied with the programme. Both mentioned better
knowledge and know-how about COPD, and peer contact
was unanimously regarded as helpful and a potential
source of motivation for patients. Some areas required im-
provement nevertheless. The major criticism made by pa-
tients and healthcare professionals related to communi-
cation. The information provided to stakeholders and the
community was deemed insufficient. Patients were faced
with practitioners outside the programme who were not
aware of it or were critical of it. They were also confused
about the evaluation and monitoring aspect intrinsically
linked to the pilot programme. Healthcare professionals
said they wanted more information about their patients’
follow-up. A general lack of coordination between health-
care professionals was also mentioned. Finally, GPs ex-
pressed difficulties in motivating patients to follow med-
ical recommendations and change life habits. Despite these
criticisms, qualitative data revealed that the intervention
tests, number of exacerbations (past 12 months), CAT score and mM-
RC score. ‡ mMRC scale is divided into five categories: 0 = breathless
with strenuous exercise, 1 = short of breath when hurrying on level
ground or walking up a slight hill, 2 = walks slower than people of the
same age because of breathlessness, or has to stop for breath when
walking at own pace, 3 = has to stop for breath after walking about 100
yards or after a few minutes, 4 = too breathless to leave the house or
breathless while dressing.
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was well received by patients and healthcare professionals,
confirming the acceptability of the programme. The results
from the patient satisfaction questionnaire at the end of the
programme were consistent with this conclusion, with 96%
of patients giving a positive evaluation to the programme,
and 85% stating they would recommend the programme to
another person living with COPD (n = 46).
Outcome evaluation: effectiveness
Primary and secondary outcomes before (baseline) and af-
ter (12 months) the intervention are presented in detail in
table 3. Only patients with complete data were included in
these analyses (n = 46).
Primary outcomes
The mastery domain of the disease-specific quality-of-life
score (CRQ) increased significantly at 12 months (+0.5;
p = 0.01). A significant improvement on two generic
HRQoL dimensions was also observed: social functioning
(+10.3; p <0.01) and role limitations due to emotional
problems (+14.8; p = 0.02). Whereas these three dimen-
sions presented changes that can be considered clinically
significant, the other dimensions or domains of (health-re-
lated) quality of life remained stable.
The proportion of patients with one or more hospitalisa-
tions (all causes) and the proportion of patients with one
or more hospitalisations for acute exacerbations were not
statistically different between baseline and follow-up, even
though the proportion of patients with one or more hospi-
talisations (all-causes) decreased from 40% to 27%.
Secondary outcomes
Both the mean self-efficacy score – corresponding to the
patients’ beliefs in their capabilities to manage COPD –
and the results of the sit-to-stand test increased signifi-
cantly between baseline and 12 months (+0.6, p<0.01 and
+2.5, p<0.01, respectively). Severity of symptoms, mea-
sured as the CAT and mMRC scores, as well as the fre-
quency of exacerbations, remained stable at 12 months. No
change was observed in the number of emergency depart-
ment visits / unscheduled physician visits. Regarding risk
factors, results showed that influenza vaccination cover-
age improved significantly at 12 months (70% at baseline
vs 87% at 12 months), whereas there was no significant
change in the proportion of current smokers between base-
line and 12-month follow-up (43 vs 38%).
Comparison with the control group (patients from the
Swiss COPD Cohort)
The demographic and medical characteristics of both
groups were similar except for lung function and number
of exacerbations, which were lower in the intervention
group, and for inhaled corticosteroid use which was much
higher in the intervention group. Evolution differences of
dyspnoea measures (mMRC), number of exacerbations
and smoking status are shown in table 4. These results sug-
gest that (1) the proportion of patients reporting at least
one exacerbation in the previous year or in the previous six
months increased less strongly in the intervention group
(not statistically significant); (2) the proportion of current
smokers decreased more sharply in the intervention group
(not statistically significant).
Discussion
The results of this mixed methods evaluation showed that
the implementation of a pilot COPD integrated care pro-
gramme emphasising self-management was feasible in an
alpine canton of Switzerland. The investigation of the im-
plementation process showed a suitable reach, considering
that the programme was in its pilot phase, and a good
dosage with regard to the self-management sessions, a core
component of the programme; multidisciplinarity was in
contrast less successful. In addition, whereas the evalua-
tion of fidelity showed that the intervention was delivered
according to the protocol, notwithstanding a few adjust-
ments linked to the results of the focus groups and field
constraints; acceptability among stakeholders was moder-
ately high whereas participants were highly satisfied with
the programme. Finally, exploration of the effectiveness of
this evidence-based pilot programme showed that health-
related quality of life, self-efficacy, exercise capacity, im-
munisation coverage and PACIC score improved after 12
months of participation in the programme, and compar-
isons with a matched control group suggested trends to-
wards improvements despite the absence of statistically
significant differences.
The qualitative part of the evaluation truly added value
to the quantitative evaluation. Feedback from participating
patients and healthcare professionals helped improve and
adapt the programme to the needs of those concerned. For
Table 2: Patients’ and healthcare professionals’ feedback on the programme.
Positive feedback Negative feedback
Patients
Improved knowledge on COPD mechanism and medications Objectives of the programme unclear / research side of the project confusing
Raised awareness of the presence of COPD (if denial) and the need to change
lifestyles
External healthcare professionals poorly informed about the programme
Acquired breathing techniques and stress management skills Lack of communication and coordination between healthcare professionals
Peer support Lack of impact on motivation to change lifestyles
Clarity of the education material Organisational problems (during the first year)
Healthcare professionals
Focus on healthy lifestyles (physical activity and smoking cessation) Lack of information about the programme
Peer support Difficulty in recruiting patients
Improved self-efficacy Poor transmission of information between healthcare professionals
Duration of the programme Absence of feedback on patients monitoring
Action plan for acute COPD exacerbations Measures to help patients with tobacco cessation could be improved
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example, once we realised that healthcare professionals
outside the programme were poorly informed about it and
sometimes even reluctant to show interest and accompa-
ny their participating patients, and that healthcare profes-
sionals involved in the programme reported insufficient
feedback from the programme coordinator regarding their
own patients, we decided to send formal letters contain-
ing patient data to patients, pharmacists, referring GPs and
pulmonologists. Sent at entry into the programme, after
the self-management education sessions and at 12 months,
these letters included a summary table containing results
of pulmonary function tests, quality of life, physical activ-
ity level, exacerbation rate, CAT score, smoking status and
quality of inhaled medication techniques. Healthcare pro-
fessionals seemed to appreciate this easy-to-read and valu-
able information.
Another example of programme improvement following
the process evaluation relates to the use of action plans in
cases of COPD acute exacerbations. Upon finding that on-
ly two thirds of patients had received an individualised ac-
tion plan during the pilot phase, which is a key element
for reducing healthcare utilisation [18, 51], we decided to
change the procedure. At first, action plan drafting and dis-
tribution were left to the referring practitioner. Now, they
are prepared by the programme’s team involved in self-
management education sessions, who have a good under-
standing of patients’ self-efficacy. This approach, similar
to that of Benzo et al. in other settings [52], reduced practi-
Table 3: Primary and secondary outcomes.
Primary outcomes Baseline 12 months p-value
Disease specific quality of life (CRQ) (n = 46)
Dyspnoea 4.8 ± 1.5 5.1 ± 1.5 0.12
Fatigue 4.0 ± 1.5 3.9 ± 1.4 0.70
Emotion 4.3 ± 1.5 4.4 ± 1.5 0.39
Mastery 4.7 ± 1.6 5.2 ± 1.4 0.01
Generic health-related quality of life (SF-36)
Physical functioning (n = 44) 55.5 ± 26.1 54.7 ± 25.5 0.76
Role physical (n = 44) 50.0 ± 39.3 50.6 ± 40.5 0.93
Bodily pain (n = 46) 54.8 ± 26.5 57.1 ± 24.8 0.56
General health (n = 44) 42.9 ± 21.9 45.5 ± 19.0 0.23
Vitality (n = 46) 47.4 ± 21.9 45.4 ± 20.6 0.47
Social functioning (n = 45) 59.7 ± 30.3 70.0 ± 26.4 <0.01
Role emotional (n = 45) 48.0 ± 44.1 62.8 ± 41.6 0.02
Mental health (n = 46) 56.3 ± 23.8 60.5 ± 22.8 0.09
Hospitalisations
≥1 hospitalisations (all-causes) in previous year (n = 45) 18 (40.0) 12 (26.7) 0.21
≥1 hospitalisations for acute exacerbations in previous year (n = 38) 8 (21.1) 7 (18.4) 1.00
Secondary outcomes
Self-efficacy (n = 45) 7.9 ± 1.4 8.5 ± 1.2 <0.01
Symptoms and acute exacerbations
CAT score (n = 46) 17.3 ± 7.4 17.6 ± 8.3 0.73
mMRC score (n = 46) 2.0 ± 1.1 1.8 ± 1.1 0.20
Number of exacerbations in previous year (n = 38) 1.53 ± 1.6 1.58 ± 1.7 0.87
≥1 exacerbations in previous year (n = 38) 24 (63.2) 25 (65.8) 1.00
Exercise capacity
6 min walking test, m (n = 31) 429.6 ± 115.1 449.6 ± 102.2 0.15
Sit-to-stand test (n = 37) 20.6 ± 6.4 23.1 ± 6.7 <0.01
Preventative measures
Current smoker* (n = 42) 18 (42.9) 16 (38.1) 0.69
Influenza vaccination in previous year (n = 46) 32 (69.6) 40 (87.0) <0.01
Pneumococcal vaccination in the last 5 years* (n = 37) 22 (59.5) 26 (70.3) 0.22
Healthcare utilisation
≥1 ER visits / unscheduled physician visits in previous year (n = 45) 19 (42.2) 17 (37.8) 0.82
Family physician visits in the previous year (n = 45) 6.5 ± 4.9 6.5 ± 4.7 1.00
≥1 pulmonologist visits in the previous year (n = 46) 34 (73.9) 38 (82.6) 0.34
Congruence with CCM (PACIC score) (n = 46) 2.2 ± 0.9 3.4 ± 1.0 <0.01
CAT = COPD Assessment Test; CCM = Chronic Care Model; CRQ = Chronic Respiratory Questionnaire; ER = emergency room; mMRC = modified Medical Research Council;
PACIC = Patient Assessment of Chronic Illness Care; SF-36 = Short Form 36. Data are presented as mean ± SD or n (%). Bold values are marking statistically significant differ-
ence (p <0.05). * Data reported by GPs at baseline and by patients at 12 months follow-up.
Table 4: mMRC score, number of exacerbations and proportion of current smoker: within and between group differences at 12 months.
Intervention group Control group
Baseline 12 months Difference Baseline 12 months Difference
Difference in differ-
ences
mMRC score n = 46 2.0 ± 1.1 1.8 ± 1.1 −0.2 (−0.5–0.1) 1.8 ± 0.9 1.9 ± 0.9 0.1 (0.0–0.3) −0.3 (−0.7–0.0)
≥1 exacerbations
in last 6/12 months
n = 38 63.2 ± 7.8% 65.8 ± 7.7% 2.6%
(−19.1–24.0%)
21.1 ± 4.7% 28.9 ± 5.2% 7.9% (−4.9–20.4%) −5.3% (−30.4–19.7%)
Current smoker n = 42 42.9 ± 7.6% 38.1 ± 7.5% −4.8%
(−16.5–7.2%)
38.1 ± 5.3% 35.7 ± 5.2% −2.4% (−7.6–2.8%) −2.4% (−15.2–10.7%)
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tioners’ workload and increased the number of action plans
delivered to patients.
Negative feedback allowed us to improve the intervention,
but positive aspects highlighted during the evaluation are
promising. Patients’ reports of improved COPD knowl-
edge, improved breathing techniques skills to manage dys-
pnoea, usefulness of peer support and recognition of the
clarity of the “Living Well with COPD” course material,
confirmed the appropriateness and utility of the self-man-
agement education group sessions. Our pilot programme
also appears effective in term of quality of life and exercise
capacity, which is consistent with results of recent meta-
analyses on self-management COPD programmes [13, 14].
Furthermore, participants increased their self-efficacy
score, showing better confidence in their capabilities to
manage their disease, thus confirming the effectiveness
of self-management education as reported by patients and
demonstrated before by Stellefson et al. [53]. Our pilot
study did not allow us to confirm a reduction of hospi-
talisations, unlike other studies on implementation of the
“Living Well with COPD” programme [18, 20]. This might
be due to the low prevalence of severe exacerbations be-
fore entry into the programme. For safety reasons, we
choose in the first year of our programme to include only
patients in a stable condition, excluding those recently ad-
mitted for COPD exacerbations.
Effectiveness of integrated care programmes might be im-
proved by good training of the programme staff and fideli-
ty to the intervention. Regular evaluations, involvement of
the programme leaders, formal feedbacks about strengths
and weaknesses, individualised multidisciplinary assess-
ment of patients and a centralised database with patients’
electronic reports to insure easy quality control represent
some necessary elements. Future developments of the pro-
gramme will target multidisciplinarity, a component that
did not receive enough attention in the pilot phase; this
is particularly important since the development of mutu-
al trust and clarity around each actor’s role is a complex
process that requires time. Up to now, the promotion of
the programme during multidisciplinary seminars, physi-
cian-specific meetings and via traditional media and re-
gional newspapers led to its better acceptability, and also
improved interprofessional collaboration between health-
care professionals involved in COPD care; in addition, it
increased the coverage of the programme.
The main strengths of this project were that it was con-
ducted under real-world conditions, that it combined both
a process (feasibility and acceptability) and an outcome
(effectiveness) evaluation, and that it took advantage of
both qualitative and quantitative methods. This choice en-
abled the continual adaptation and improvement of the pro-
gramme, and confirmed that COPD patients participating
in the programme benefited from it. Our results need nev-
ertheless to be interpreted with caution on account of the
following main limitations. First, the control group was
not randomly selected. However, we used propensity score
matching to compare the intervention group to the con-
trol group (the Swiss COPD Cohort), which allowed us
to adjust for patient age, gender and CAT score, but not
for other variables that could be associated with outcomes.
Therefore, our results related to the effectiveness of the
programme need to be interpreted with caution. Second,
the sample size for the effectiveness analyses (46 obser-
vations) was small, conferring low power to detect dif-
ferences and make robust conclusions about effectiveness.
However, this is not problematic, since the primary target
of the evaluation was not to assess its effectiveness, be-
cause the programme was in its pilot phase and only in-
cluded a small number of patients. In addition, the effec-
tiveness of integrated care programmes for COPD patients
has been reported in other studies [13, 14]. Third, clini-
cal measures were collected as part of routine clinical as-
sessment of COPD patients to monitor their evolution; they
were not collected to prove the effectiveness of COPD in-
tegrated care programmes per se. In that context, the pos-
itive trends towards effectiveness, which are in line with
previous results, are encouraging, even if they need to be
interpreted carefully. Fourth, besides limitations associat-
ed with pre-post study design, selection bias cannot be ex-
cluded, since patients participating in this programme were
volunteers and patients lost to follow-up were on aver-
age less symptomatic. Finally, the implementation of com-
plex interventions makes the identification of causal ef-
fects very difficult, as we cannot associate an outcome to
a specific component. However, systematic reviews have
shown that the implementation of one single or two com-
ponents of the Chronic Care Model are associated with
significantly improved clinical and process outcomes [54,
55].
Conclusions
This evaluation demonstrated that a community-based
COPD integrated care programme emphasising self-man-
agement education is both feasible and acceptable in an
alpine and rural canton of Switzerland. Improvement in so-
cial and emotional dimensions of health-related quality of
life, self-efficacy, exercise capacity, COPD knowledge and
breathing technique skills tend to confirm the known bene-
fits of integrated care with self-management education for
COPD patients. Considering the specificities of the can-
ton of Valais in term of geographical spread, fragmenta-
tion of care and lack of familiarity of primary care physi-
cians with similar programmes for other chronic diseases,
the implementation of the programme can be considered as
successful overall even if some components, such as mul-
tidisciplinarity and information transfer, need to be further
developed. An extension of the programme to the German-
speaking part of the canton is planned, and a nation-wide
programme, led by the Swiss Lung League and involving a
variety of healthcare stakeholders, is currently being devel-
oped. To achieve successful implementation in other set-
tings, rigorous organisation is required, and fidelity to the
designed intervention should be secured and regularly ver-
ified, while leaving some leeway to adapt if necessary. It
is also important to allow integrated care programmes to
run their course, since the lack of familiarity with nonphar-
macological interventions among healthcare professionals
means that changes in care take time.
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